Papa Medical Inc.
PAPADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ropivacaine nebulization
Ovarian Cysts
Cetuximab
Colorectal Cancer
Mesenchymal stromal cell low dosage-80*10^6 cells
Traumatic Brain Injury With Loss of Consciousness
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ropivacaine nebulization | Phase 3 | Ovarian Cysts | - | - |
Cetuximab | Phase 2 | Colorectal Cancer | - | - |
Mesenchymal stromal cell low dosage-80*10^6 cells | Phase 2 | Traumatic Brain Injury With Loss of Consciousness | - | - |
Frequently asked questions
What is in Papa Medical Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Papa Medical Inc.'s (PAPA) pipeline across Phase 3, Phase 2. Its lead program is Ropivacaine nebulization (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Papa Medical Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Papa Medical Inc. (PAPA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PAPA biotech catalysts?→
Add PAPA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Papa Medical Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.